Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk ...

The issuance of this patent marks another key milestone as FluidForm Bio continues to build a strong and defensible IP portfolio and extend its leadership in bioprinted regenerative medicine. The ...

Bio announced a licensing agreement with AstralBio for a preclinical first-in-class antibody targeting Activin E, which was discovered using ...

The company has developed a proprietary natural fiber liquid known as Fybron ™, that can be injected into 3D molds to create a variety of soft goods, which in many applications is fully bio-based and ...

There are a couple of ways that protective cultures work (i.e., bio-preservation). One of these mechanisms is that protective cultures can produce short chain organic acids, like propionic or acetic ...

An icon of 3 horizontal dots. An icon of a paper envelope. An icon of a facebook f logo. An icon of a digital camera. An icon of a house. An icon of the Instagram logo. An icon of the LinkedIn logo.

But behind his electric play and clutch performances lies a deeply personal motivation — one that’s captured in just two words on his Instagram bio: “RipGranda.” For Clayton, this tribute ...

Some Trump administration officials have declined to answer questions from several journalists on the basis of their email signatures. By Michael M. Grynbaum The Trump administration formally ...

The impact: 94% of biotech firms anticipate surging manufacturing costs from tariffs on the EU, while tariffs on Canada and China would have a similar impact, a March survey of BIO members found.

South Ko­re­an biotech ABL Bio has lined up an­oth­er plat­form li­cense agree­ment with a Eu­ro­pean phar­ma gi­ant in the area of neu­rode­gen­er­a­tive dis­eases.

The image of the flipped logo has been edited to add "eyes" so that it more closely resembles a KKK hood. On April 1, 2025, TikTok user @thedisciplinedfatkid posted a video (archived) in which he ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier. GSK is fronting £38.5 million (nearly $50 million), in a partnership with ...